Risk-profile and outcome of small papillary and follicular thyroid carcinomas (≤1 cm)

NuklearMedizin

Volumn 47, Issue 5, 2008, Pages 188-193

  Rahbar, K ^a   Hutzenlaub, V ^a   Fischer O, R J ^a   Schober, ^a   Riemann, B ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Distant metastasis; Extrathyroidal growth; Lymph node metastasis; Papillary and follicular thyroid carcinoma; Radioiodine ablation; Recurrence; Tumour size

Indexed keywords

IODINE 131;

ADULT; ARTICLE; CANCER RECURRENCE; CANCER SIZE; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; RISK ASSESSMENT; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; ADENOCARCINOMA; CANCER STAGING; MIDDLE AGED; PAPILLARY CARCINOMA; PATHOLOGY; RETROSPECTIVE STUDY; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THYROID TUMOR; TREATMENT OUTCOME;

ADENOCARCINOMA, FOLLICULAR; ADULT; CARCINOMA, PAPILLARY; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; RETROSPECTIVE STUDIES; RISK ASSESSMENT; THYROID NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TREATMENT OUTCOME;

EID: 58149335382     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.3413/nukmed-0147     Document Type: Article

References (46)

1. Appetecchia M, Scarcello G, Pucci E et al. Outcome after treatment of papillary thyroid microcarcinoma. J Exp Clin Cancer Res 2002; 21: 159-164.
2. Baloch ZW, LiVolsi VA. Microcarcinoma of the thyroid. Adv Anat Pathol 2006; 13: 69-75.
3. Baudin E, Travagli JP, Ropers J et al. Microcarcinoma of the thyroid gland: the Gustave-Roussy Institute experience. Cancer 1998; 83: 553-559.
4. Bergamaschi R, Becouarn G, Ronceray J et al. Morbidity of thyroid surgery. Am J Surg 1998; 176: 71-75.
5. Biermann M, Pixberg MK, Dorr U et al. Guide-lines on radioiodine therapy for differentiated thyroid carcinoma: impact on clinical practice. Nuklearmedizin 2005; 44: 229-234, 236-237.
6. Biermann M, Pixberg MK, Schuck A et al. Multicenter study differentiated thyroid carcinoma (MSDS). Diminished acceptance of adjuvant external beam radiotherapy. Nuklearmedizin 2003; 42: 244-250.
7. Biermann M, Schober O. Multizentrische Studie Differenziertes Schilddrusenkarzinom Studiengruppe. How many high-risk patients with differentiated thyroid cancer need a "Center" per year? Nuklearmedizin 2002; 41: 61-62.
8. Biondi B, Filetti S, Schlumberger M. Thyroid-hormone therapy and thyroid cancer: a reassessment. Nat Clin Pract Endocrinol Metab 2005; 1:32-40.
9. Cappelli C, Castellano M, Braga M et al. Aggressiveness and outcome of papillary thyroid carcinoma (PTC) versus microcarcinoma (PMC): a mono-institutional experience. J Surg Oncol 2007; 95: 555-560.
10. Cappelli C, Pirola I, Braga M et al. Prognostic factors in well-differentiated thyroid carcinoma in patients treated and followed in the same institution. Ann Ital Chir 2006; 77:107-113.
11. Cheema Y, Repplinger D, Elson D et al. Is tumor size the best predictor of outcome for papillary thyroid cancer? Ann Surg Oncol 2006; 13: 1524-1528.
12. Cooper DS, Doherty GM, Haugen BR et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006; 16:109-142.
13. DeLellis RA, Lloyd RV, Heitz, PU et al. World Health Organisation Classification of Tumours. Pathology and Genetics of Tumours of Endocrine organs. Lyon: IARC Press 2004.
14. Dietlein M, Dressier J, EschnerWetal. Procedure guidelines for radioiodine therapy of differentiated thyroid cancer (version 3). Nuklearmedizin 2007; 46: 213-219.
15. Dietlein M, Dressier J, Eschner W et al. Procedure guideline for iodine-131 whole-body scintigraphy for differentiated thyroid cancer (version 3). Nuklearmedizin 2007; 46: 206-212.
16. Dietlein M, Dressler J, Farahati J et al. Procedure guidelines for radioiodine therapy of differentiated thyroid cancer (version 2). Nuklearmedizin 2004;43:115-120.
17. Dralle H. Maligne Schilddrüsentumoren, für die Deutsche Krebsgesellschaft. Kurzgefasste interdisziplinäre Leitlinien 2006. Empfehlungen zur Diagnostik und Therapie maligner Erkrankungen. München: W Zuckschwerdt 2006; 53-61.
18. Dralle H, Sekulla C. Thyroid surgery: generalist or specialist? Zentralbl Chir 2005; 130:428-433.
19. Fink A, Tomlinson G, Freeman JL et al. Occult micropapillary carcinoma associated with benign follicular thyroid disease and unrelated thyroid neoplasms. Mod Pathol 1996; 9: 816-820.
20. 131I whole-body scintigraphy in paediatric patients with differentiated thyroid cancer. Nuklearmedizin 2007; 46: 224-231.
21. FriedrichT, Steinert M, Keitel R et al. Incidence of damage to the recurrent laryngeal nerve in surgical therapy of various thyroid gland diseases : a retrospective study. Zentralbl Chir 1998; 123: 25-29.
22. Harach HR, Franssila KO, Wasenius VM. Occult papillary carcinoma of the thyroid. A "normal" finding in Finland. A systematic autopsy study. Cancer 1985; 56: 531-538.
23. Hay ID, Grant CS, van Heerden JA et al. Papillary thyroid microcarcinoma: a study of 53 5 cases observed in a 50-year period. Surgery 1992; 112: 1139-1147.
24. Ito Y, Uruno T, Nakano K et al. An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. Thyroid 2003; 13: 381-387.
25. Khoo ML, Beasley NJ, Ezzat S et al. Overexpression of cyclin D1 and underexpression of p27 predict lymph node metastases in papillary thyroid carcinoma. J Clin Endocrinol Metab 2002; 87:1814-1818.
26. Khoo ML, Freeman JL, Witterick IJ et al. Underexpression of p27/Kip in thyroid papillary microcarcinomas with gross metastatic disease. Arch Otolaryngol Head Neck Surg 2002; 128: 253-257.
27. Kucuk NO, Tari P, Tokmak E et al. Treatment for microcarcinoma of the thyroid-clinical experience. ClinNucl Med 2007; 32: 279-281.
28. Lerch H, Schober O, Kuwert T et al. Survival of differentiated thyroid carcinoma studied in 500 patients. J Clin Oncol 1997; 15: 2067-2075.
29. Lin KD, Lin JD, Huang MJ et al. Clinical presentations and predictive variables of thyroid micro
30. carcinoma with distant metastasis. Int Surg 1997; 82:378-381.
31. Machens A, Holzhausen HJ, Dralle H. The prognostic value of primary tumor size in papillary and follicular thyroid carcinoma. Cancer 2005; 103: 2269-2273.
32. Mazzaferri EL, Kloos RT Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001; 86:1447-1463.
33. Pacini F, Schlumberger M, Dralle H et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006; 154: 787-803.
34. Pellegriti G, Scollo C, Lumera G et al. Clinical behavior and outcome of papillary thyroid cancers smaller than 1.5 cm in diameter: study of 299 cases. J Clin Endocrinol Metab 2004; 89: 3713-3720.
35. Piersanti M, Ezzat S, Asa SL. Controversies in papillary microcarcinoma of the thyroid. Endocr Pathol 2003; 14:183-191.
36. Prim MP, de Diego JI, Hardisson D et al. Factors related to nerve injury and hypocalcemia in thyroid gland surgery. Otolaryngol Head Neck Surg 2001;124:111-114.
37. Riemann B, Schober 0. Das kleine Schilddrüsenkarzinom. Nuklearmedizin 2007; 46:113-114.
38. Rosai J, LiVolsi VA, Sobrinho-Simoes M et al. Renaming papillary microcarcinoma of the thyroid gland: the Porto proposal. Int J Surg Pathol 2003; 11:249-251.
39. Roti E, Rossi R, Trasforini G et al. Clinical and histological characteristics of papillary thyroid microcarcinoma: results of a retrospective study in 243 patients. J Clin Endocrinol Metab 2006; 91 : 2171-2178.
40. Satge D, Grob JC, Pusel J et al. Thyroid microcarcinoma with a fatal outcome and 34 other unusually aggressive cases reported in the literature. Arch Anat Cytol Pathol 1990; 38:143-151.
41. Sawka AM, Thephamongkhol K, Brouwers M et al. Clinical review 170: A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab 2004; 89: 3668-3676.
42. Schonberger J, Marienhagen J, Agha A et al. Papillary microcarcinoma and papillary cancer of the thyroid <1 cm: Modified definition of the WHO and the therapeutic dilemma. Nuklearmedizin 2007;46:115-120.
43. Schuck A, Biermann M, Pixberg MK et al. Acute toxicity of adjuvant radiotherapy in locally advanced differentiated thyroid carcinoma. First results of the multicenter study differentiated thyroid carcinoma (MSDS). Strahlenther Onkol 2003; 179: 832-839.
44. Shattuck TM, Westra WH, Ladenson PW et al. Independent clonal origins of distinct tumor foci in multifocal papillary thyroid carcinoma. N Engl J Med 2005; 352:2406-2412.
45. Sherman SI. Thyroid carcinoma. Lancet 2003; 361:501-511.
46. Wittekind C, Meyer HJ, Boots E TNM classification of malignant tumors. Berlin: Springer 2002.